TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis
Brief Summary: To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis


Options:
A: The Rates of Complete Symptom Relief (at the 20 weeks after the end of initial treatment.)
B: Difference between the proportion of patients who discontinued on-demand esomeprazole treatment versus continuous esomeprazole treatment due to unsatisfactory treatment as determined by the investigator in consultation with the patient (6 months)
C: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment (From randomisation to day 14)
D: Mean Change From Baseline to Month 12 for Hemoglobin Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Hematocrit Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Red Blood Cell Count Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Mean Corpuscular Hemoglobin Concentration Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Platelet Count Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for White Blood Cell Count Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Blood Urea Nitrogen Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Creatinine Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Calcium Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Inorganic Phosphorus Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Total Bilirubin Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Alkaline Phosphatase Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Aspartate Aminotransferase Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Alanine Aminotransferase Values (Baseline and Month 12); Mean Change From Baseline to Month 12 for Serum Gastrin Levels (Baseline and Month 12); Mean Change From Baseline to Month 12 for Systolic Blood Pressure (Baseline and Month 12); Mean Change From Baseline to Month 12 for Diastolic Blood Pressure (Baseline and Month 12); Mean Change From Baseline to Month 12 for Pulse Rate (Baseline and Month 12); Changes From Baseline to Final Visit in Antrum Biopsy Results (Baseline and Final Visit (up to 12 months)); Changes From Baseline to Final Visit in Fundus Biopsy Results (Baseline and Final Visit (up to 12 months))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Trail of Continues Methadone Maintenance Versus Detoxification in Jail
Brief Summary: Methadone maintenance treatment (MMT) has been shown to be effective in reducing drug use, criminal activity and recidivism. Given this effectiveness, maintaining individuals who are enrolled in community MMT when committed to the Department of Corrections for short term incarceration would improve post release outcomes. However, this is rarely practiced in the United States. Current practice at the Rhode Island Department of Corrections is to detox inmates on methadone within 30 days of being incarcerated. More than 75% of these individuals are incarcerated for less than six months. The period immediately after release from incarceration is a particularly high-risk time for HIV and other problems including drug relapse and overdose.

The investigators hypothesize that inmates who are incarcerated for 6 months or less will have better outcomes and cost the state less money if they are maintained on their methadone dose and relinked to their community clinic at release, than the current practice of detoxification.


Options:
A: Rates of HIV Seroconversion (From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years); Renal Toxicity (Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years); Adverse Events (Up to 6.9 years)
B: Graduation from juvenile drug court (Collected once at 12 months from intake/baseline.); Change in substance use (Baseline at the begining of the study, and then at 6, 12, 18, and 24 months after baseline); Change in delinquency (Baseline, and then at 6, 12, 18, and 24 months after baseline); Change in Mental health symptoms (Baseline, 6, 12, 18 and 24 months after baseline); Change in Family functioning (Baseline, 6, 14, 18, and 24 months after baseline); Length of treatment (Collected once, at 12 months after baseline); Change in arrests (12 months before intake through 24 months after intake); Change in substance use (Intake, 6, 12, 18, 24 months after intake); Change in substance use (Intake, 6, 12, 18 and 24 months after intake)
C: Post-Release Opioid Relapse (Four weeks post-release)
D: Time to post release treatment engagement (30 days post release); Reduction of HIV risk behaviors (12 months); Time to relapse (30 days post release); Cost effectiveness (12 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: 7-day point prevalence of abstinence, 9-12 week continuous abstinence, 9-26 week continuous abstinence (9-12 weeks; 9-26)
B: biologically verified smoking cessation or reduction (8 weeks and delivery)
C: 4 week continuous quit rate ( 4 week CQR ) for weeks 9 -12
D: Primary efficacy and Safety endpoint: (within 12 month from enrollment)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: Proportion of Cocaine Positive Urine Tests Per Week (Weekly Measures over 12 weeks)
B: seven-day point prevalence of smoking reduction, defined as 50 % reduction in serum cotinine levels compared to baseline (end of treatment)
C: biologically verified smoking cessation or reduction (8 weeks and delivery)
D: Emotional Reactivity By Pharmacotherapy (Baseline to 1 month); Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele (Baseline to 1 month)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: Point prevalence of smoking cessation (those who have quitted smoking and have not smoked in the past week prior to the assessment date). (52 weeks after starting the treatment)
B: biologically verified smoking cessation or reduction (8 weeks and delivery)
C: Self-reported continuous abstinence of smoking and exhaled carbon monoxide levels less than 10 ppm as measured and recorded by the research nurse at weeks 12 and 52. (1 year)
D: Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) (Week 9 through Week 12)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: biologically verified smoking cessation or reduction (8 weeks and delivery)
B: Rating of urges to smoke one week after the target quit date assessed by Mood and Physical Symptoms Scale (1 week)
C: Seven-day point prevalence and treatment or treatment strategy (At week 6); Main effects of varenicline and nicotine patch + lozenge on smokers who remain on these medications throughout the trial as documented in questionnaires (Up to 12 weeks); Probability of response at week 12 conditional on response at week 6 and continuation of treatment (At 12 weeks); Probability of response at week 12 conditional on non-response at week 6 and continuation of treatment (At 12 weeks); Probability of response at week 12 conditional on non-response at week 6 and augmentation of treatment (At 12 weeks); Probability of response at week 12 conditional on non-response at week 6 and treatment switching (At 12 weeks); Probability that treatment continuation, switching, or augmentation confers benefit conditional upon failing to quit after the initial treatment with nicotine patch + lozenge for six weeks (12 weeks); Probability that treatment continuation, switching, or augmentation confers benefit conditional upon failing to quit after initial treatment with varenicline for six weeks (12 weeks)
D: Survival abstinence rate with maintenance treatment (48 weeks after start of treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: biologically verified smoking cessation or reduction (8 weeks and delivery)
B: Determine the efficacy of combined therapy (VRN+nicotine patches) versus monotherapy (VRN+placebo patches) in smoking cessation assessed as continuous abstinence rate (CAR) from week 2 to week 12. (Participants will be followed for the duration of treatment, 12 weeks.)
C: seven-day point prevalence of smoking reduction, defined as 50 % reduction in serum cotinine levels compared to baseline (end of treatment)
D: 4 week continuous quit rate ( 4 week CQR ) for weeks 9 -12

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: Background:

Aim:

Clinical evaluation of the effectiveness of two different polyethylene glycol doses for the maintenance treatment of functional constipation in children.

Study design:

Randomized, open-label trial.

Randomized, double-blind, placebo controlled trial.


Options:
A: Efficacy (4 weeks of observation); Efficacy (7 days)
B: Bowel movement frequency (week 4)
C: Symptom Based Weekly Total Sum Score (TSS) Over 52 Weeks (Baseline (Week 0), Week 1, 2, 3, 4, 8, 12, 26, 52); Change From Baseline in Total Sum Score (TSS) at Week 52 (Baseline, Week 52); Short Term Change of Total Sum Score (TSS): Average of Weeks 1 to 8 Minus Baseline (Average of Weeks 1 to 8); Long Term Change of Total Sum Score (TSS): Average of Weeks 26 and 52 Minus Baseline (Average of Weeks 26 and 52); Overall Change of Total Sum Score (TSS): Average of all Diaries Obtained Minus Baseline (Average up to 52 weeks); Dose Range Determination: Mean Dose Based on Sachets Used (Up to 52 weeks.); Dose Range Determination: Mean Dose per Kilogram Body Weight Based on Sachets Used (Up to 52 weeks)
D: therapeutic success (passing ≥ 3 stools per week, with no loosening of stool). (the number and consistency of the stool will be recorded at 6th week of intervention)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Falls (1 year)
B: fall-related injury (Study duration = 18 months. Outcome measured for each patient for duration of stay in ward (approx. 30 days).)
C: N/A
D: Successful medication discontinuation (4 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Sudden death: death of endogenous origin within 24 hours after acute onset; Cerebrovascular events: new occurrence or recurrence of a stroke or transient ischemic attack; Cardiac events: new occurrence, aggravation, or recurrence of heart failure, angina pectoris, or acute myocardial infarction; Renal dysfunction: serum creatinine ≥4.0 mg/dl, end stage renal disease, doubling of serum creatinine (however, creatinine ≤2.0 mg/dl is not regarded as an event); Vascular events: new occurrence or aggravation of dissecting aneurysm of aorta, arteriosclerotic occlusion of peripheral artery
B: Medication possession ratio (MPR), gaps and persistence in medicines use (Seven months after recruitment)
C: Successful medication discontinuation (4 months)
D: Medication Appropriateness Index (MAI) score (Change from baseline MAI score at 6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Successful medication discontinuation (4 months)
B: Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours (Baseline and EOT (up to 12 weeks)); Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 Hours (Baseline and EOT (up to 12 weeks))
C: DBI decrease (3 months)
D: Total standardized daily dose (TSDD) - from medical records (12 months); Total standardized daily dose (TSDD) - self-report medication inventory (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Successful medication discontinuation (4 months)
B: Hospitalizations and/or mortality (From Baseline to Month 18)
C: number of unplanned hospitalizations (6 months)
D: Improvement of drug prescribing (Participants will be followed for the duration of hospital stay, an expected average of 12 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator
Brief Summary: Sudden cardiac death (SCD) due to a ventricular arrhythmia is a serious cause of cardiovascular death in Canada. The implantable cardioverter defibrillator (ICD) offers high-risk patients a treatment option to reduce the incidence of SCD by delivering an internal shock to restore a normal rhythm, if needed. Definitive evidence has established the effectiveness of the ICD for reducing mortality when used as prophylaxis for SCD (a primary prevention indication). Approximately 3,700 new candidates accrue annually. Practice guidelines define the criteria to determine patient ICD candidacy for primary prevention. However, in addition to SCD risk, ICD candidates may have chronic diseases such as diabetes, renal insufficiency, hypertension, and atrial fibrillation. Thus, balancing the benefits and risks of an ICD can become complex, particularly when competing mortality risks are present. Research has recognized human costs associated with device complications and shocks affecting psychological, health related quality of life (HRQL), and morbidity outcomes. The complexities surrounding the long-term benefits/risks, complications, replacements, and shocks, warrant decision support to prepare patients to make decisions. In Canada, there is no clear framework to support patients' decision-making in the context of ICD treatment options. Decision support, using a decision aid, could moderate treatment related uncertainty and prepare patients to make active, informed, quality decisions.

Objectives: 1) develop a decision aid for ICD candidates to support quality decision-making (informed, deliberate, values-based choices), 2) to evaluate the decision aid, and 3) to determine the feasibility of conducting a trial.


Options:
A: Informed choice (2 weeks post intervention); Involvement in screening decision (2 weeks post intervention)
B: The between groups difference in the proportion of patients which achieve the treatment goals for HbA1c, blood pressure, and total cholesterol (after 12 months)
C: Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation. (Phase 1-2 (1- year))
D: Completion of colorectal cancer screening

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Brief Summary: In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those people get with recent HIV infection.

Specific objectives:

1. What proportion of people presenting with these symptoms are HIV positive at the point of seeking urgent health care?
2. What proportion of those who test negative or where the result is unclear (one rapid test positive and one negative) at first rapid HIV testing, will test positive two weeks later?
3. What is the best way (SMS, phone call or home visit) to remind people to come for the second test after two weeks?
4. Will young adults who seek urgent health care for fever, body pains, diarrhoea or an STD from pharmacies or health facilities find it acceptable to be invited for an HIV-1 test at the time of health care seeking?

Hypotheses

1. Targeted screening for AHI among patients seeking health care for symptoms compatible with AHI or sexually transmitted disease (STD) will identify AHI cases in more than 1% of those screened.
2. Intense follow-up of patients evaluated for AHI will improve rates of repeat HIV-1 testing 2-4 weeks after initial health-care seeking, relative to standard practice (i.e., recommendation to return for testing on a given date).


Options:
A: MV Coverage at 12 months of age (12 months of age)
B: HIV propensity score (0, 6 and 12 months)
C: Difference in Number and proportion of adults responding to standard appointment versus intense follow up. (2 weeks)
D: Acceptability of at least one method of effective contraception (4 months)

Answer: C